Previous Close | 8.09 |
1-Year Change | 57.39% |
6-Months Change | 2.8% |
3-Months Change | 4.66% |
Moving Avg (50d) | 7.6292 |
Moving Avg (200d) | 7.1424 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.54B |
Beta (3-Years) | 1.19 |
Revenue Growth (ttm) | 33.18% |
Net Profit Margin (ttm) | -74.43% |
Return On Assets (ttm) | -45.2% |
EPS (ttm) | -1.25 |
PE Ratio (ttm) | -6.47 |
Dividend Yield | % |
Asset Description: | BioCryst Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-21 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
7.928 | 7.686 | 7.524 | 7.281 | 6.877 | 6.472 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.